Concord Wealth Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-84
| Closed | -$9.45K | – | 955 |
|
|
2023
Q3 | $9.45K | Hold |
84
| – | – | ﹤0.01% | 627 |
|
|
2023
Q2 | $7.92K | Hold |
84
| – | – | ﹤0.01% | 641 |
|
|
2023
Q1 | $8.5K | Hold |
84
| – | – | ﹤0.01% | 611 |
|
|
2022
Q4 | $10K | Buy |
+84
| New | +$10K | ﹤0.01% | 634 |
|
|
2022
Q3 | – | Sell |
-84
| Closed | -$8K | – | 764 |
|
|
2022
Q2 | $8K | Hold |
84
| – | – | ﹤0.01% | 738 |
|
|
2022
Q1 | $8K | Hold |
84
| – | – | ﹤0.01% | 824 |
|
|
2021
Q4 | $7K | Hold |
84
| – | – | ﹤0.01% | 877 |
|
|
2021
Q3 | $8K | Sell |
84
-37
| -31% | -$3.52K | ﹤0.01% | 505 |
|
|
2021
Q2 | $12K | Buy |
121
+66
| +120% | +$6.55K | ﹤0.01% | 597 |
|
|
2021
Q1 | $5K | Buy |
+55
| New | +$5K | ﹤0.01% | 672 |
|